Kornimate/medical-research-clean huggingface dataset:
clinical features of suspected and confirmed patients of 2019 novel coronavirus infection

Conditions: Coronavirus

Summary: outbreak of 2019 novel coronavirus infection started in wuhan and quickly spread to the world. suspected patients were isolated and treated in our department. clinical data was recorded to investigate the clinical features of patients confirmed and excluded diagnosed of 2019 novel coronavirus infection.

medical date of suspected patients of 2019 novel coronavirus infection, who came to outpatient department of the third affiliated hospital of sun yat-sen university, were sent to an expert group if they met the inclusion criteria. the expert group discussed and made a decision if the patient would be admission to isolation unit. pharyngeal swabs of the patients were obtained and sent to local center for disease control and prevention (cdc) for detection the 2019 novel coronavirus after patients were admission to isolation unit. diagnosis of 2019 novel coronavirus infection was confirmed if the result was positive or excluded if two consecutive results were negative. patients' demographic data and clinical characteristics were recorded. clinical characteristics including epidemiological history, past history, personal history, symptoms, signs, blood cells count, biochemical test results, chest computed tomography (ct) images and treatment. comprehensive treatments were given to the patients.

Eligibility criteria:
inclusion criteria: 1. epidemiological history including resident of hubei province, or travel history to hubei province or exposure to suspected patients in the past two weeks. 2. symptoms like fever, fatigue, myalgia, headache, cough, sputum production, chest tightness, dyspnea, etc. 3. white blood cells decreased or were normal, or lymphocytes decreased, and chest ct images showed typical findings of viral pneumonia. exclusion criteria: 1. patients can not follow-up; 2. investigator considering inappropriate.

Keywords: 2019 novel coronavirus
aeroeclipse ii agreement

Conditions: Asthma

Summary: traditional, continuous-mode nebulizers such as the english-wright nebulizer are designed to operate continuously with tidal breathing. as inhalation accounts for only about one-third of the respiratory cycle, two-thirds of the continuously produced aerosol is lost to the environment possibly posing a hazard any fellow-patients, family members, or health-care workers in the vicinity. the english-wright has been the only american thoracic society (ats)recommended device available on the market. recently roxon medi-tech has announced the discontinuation of the english-wright nebulizer. for these reasons it is necessary to review the use of other nebulizers such as the aeroeclipse ii breath-actuated nebulizer and further validate their performance. the investigators expect to show equivalence between the aeroeclipse ii and the english-wright nebulizers.

this study would like to determine if the use of the aeroeclipse ii breath actuated nebulizer for the delivery of methacholine chloride bronchoprovocation agent to the lungs results in the same provocation concentration pc20 (provocation concentration, or dose that causes a 20% decrease in forced expiratory volume in 1 sec or fev1) as using the english-wright nebulizer for the delivery of methacholine chloride bronchoprovocation agent to the lungs.

Eligibility criteria:
inclusion criteria: 1. aged 10 to 65 years at time of recruitment into this study, 2. diagnosis of current asthma by a health care professional, 3. tidal breathing provocation concentration ≤ 16 mg/ml, 4. forced expiratory volume 1\> 65% of predicted, 5. no respiratory tract infection or allergen exposure ≥ 4 weeks, 6. able to complete 2 methacholine inhalation challenges on 2 separate days at the same time of day, at least 24-h apart, and within a 2-week period, 7. inhaled salbutamol withheld for ≥8 hours prior to testing, 8. inhaled corticosteroid maintained at same dose throughout study, 9. inhaled formoterol and salmeterol withheld for ≥36 hours prior to testing. exclusion criteria: 1. those born prematurely (more than 4 weeks early of the calculated date), 2. those with chronic health conditions like diabetes or cystic fibrosis, 3. smokers.

Keywords: methacholine challenge nebulizer english-wright aeroeclipse ii
intraoperative hemodynamic instability during unilateral adrenalectomy for pheochromocytoma

Conditions: Pheochromocytoma; Non-Secretory Adrenal Adenoma

Summary: pheochromocytomas are tumors of the adrenal gland that develop from cells producing adrenaline and noradrenaline. consequently, intraoperative blood pressure variations (hypertensive and hypotensive episodes) are characteristic of pheochromocytoma surgery, when these tumors are removed. however, recommendations for the management of these tumors are based on data essentially dating from the 1960s-1990s. since then, anesthesia and surgery for patients with pheochromocytoma have evolved considerably, and have become more effective with time. in these circumstances, a review of the current situation is necessary. the aim of this study is to investigate the intraoperative hemodynamic changes observed in patients undergoing adrenalectomy for pheochromocytoma, comparing them with the hemodynamic profile observed in patients undergoing adrenal surgery for a pathology other than pheochromocytoma (control group).

each patient included in this study underwent unilateral adrenalectomy for adrenal pathology during the inclusion period. for each patient included, intraoperative hemodynamic data were collected every 20 seconds by the monitoring system used by the anesthesia team (vitalsignscapture v1.004 program via rs232 port). for each patient, the hi score (a clinical tool validated in two previously published articles) was calculated for the intraoperative period (time between induction of anesthesia and patient discharge from the operating room). this enabled a comparison to be made between patients operated on for pheochromocytoma (30 patients) and patients operated on for a cause other than pheochromocytoma (30 patients).

Eligibility criteria:
inclusion criteria: * patients operated on for unilateral adrenal pathology by laparosocopic approach (pheochromocytoma and non-pheochromocytoma) exclusion criteria: * patients operated on for unilateral adrenal pathology by laparosocopic approach (pheochromocytoma and non-pheochromocytoma) * patients operated on for bilateral adrenal pathology

Keywords: adrenalectomy
a pharmacokinetic substudy of the tde-ph-304 protocol

Conditions: Pulmonary Arterial Hypertension

Summary: a sub-study to the tde-ph-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.

as noted above in "brief summary".

Eligibility criteria:
inclusion criteria: 1) only subjects who are eligible for and have entered into protocol tde-ph-304 may participate in this substudy. exclusion criteria: 1. the subject must voluntarily give informed consent to participate in the substudy. 2. no dose changes to study drug are made within 5 days of the pharmacokinetic (pk)substudy visits. 3. no additions or deletions to concurrent medications are made within 7 days of the pharmacokinetic substudy visit. note: changes to diuretics and/or anticoagulants are permitted. 4. the preceding evening dose of study drug should have been taken 9 to 13 hours prior to the bid dose and 6-10 hours prior to the tid morning dose of study drug to ensure a trough level of study drug for pk sampling. 5. subject dosing of study drug on the day of pk sampling must be observed in the clinic by study personnel. 6. subject has not experienced a significant loss of blood (\> 450 ml) within the last 6 weeks of the pharmacokinetic substudy visit. 7. the subject must not be receiving any cyp 2c8 inducers or inhibitors
treatment of patients with takayasu arteritis complicated with pulmonary artery involvement

Conditions: Takayasu Arteritis With Pulmonary Artery Involvement; Percutaneous Transluminal Pulmonary Angioplasty; PAH Targeted Medication

Summary: 1. evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement 2. evaluate the efficacy of fapi in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

at baseline, fapi and fdg are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. fapi is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

Eligibility criteria:
inclusion criteria: * patients diagnosed with takayasu arteries with pulmonary arteries involvement exclusion criteria: * patients had pulmonary artery stenosis arising from cteph, fibrosing mediastinitis and congenital pulmonary artery stenosis

Keywords: percutaneous transluminal pulmonary angioplasty, takayasu arteritis with pulmonary artery involvement
intra-arterial treatment of pancreatic cancer using the renovocath™ rc120 catheter

Conditions: Pancreatic Neoplasms

Summary: this is an observational study to assess patient survival and clinical outcomes after the renovocath™ rc120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.

this is an observational, registry study to assess patient survival and clinical outcomes of the renovocath™ rc120 catheter when used to deliver chemotherapeutic agents to pancreatic tumors. blood samples will be drawn in a subset of patients to assess the systemic concentration of the chemotherapeutic agent. the renovocath™ rc120 catheter is an endovascular multi-lumen, two-handled catheter designed to isolate variable segments of arteries supplying the target organ using two slideable, compliant balloons. upon inflation of the proximal occlusion balloon and the distal occlusion balloon, the catheter may isolate the selected site to specifically deliver radiopaque and therapeutic agents including, but not limited to chemotherapeutic drugs.

Eligibility criteria:
inclusion criteria: * 18 years of age * diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma confirmed by histology or cytology * without current myelotoxicity and with sufficient health status to undergo a catheterization procedure * willing to provide informed consent and comply with the required follow-up. exclusion criteria: * have received prior chemotherapy and/or radiation therapy within 14 days prior to the first intra-arterial treatment. * currently participating in another active drug or device study or registry protocol that would interfere with this study. * vulnerable populations: prisoners, pregnant or breastfeeding females.
effect of propolis application on burn healing

Conditions: Burns; Burn Wound

Summary: this experimental study will be carried out at ege university laboratory animals application and research center to identify the efficacy of 10% propolis and 15% propolis on wound healing in a second-degree superficial burn wound. in the study, 36 adult (8-12 week old) wistar-albino rats with a weight of 200-300 grams will be used in each group. each group will include 6 rats. stratified randomization will be used to randomize rats according to their gender and weight. after randomization, a burnt area will be created on the back of the rats and dressings will be made every day. following the creation of the burn, biopsy samples will be taken on the 3rd, 7th, 14th and 21st days and at the light microscopic level; bulla, erythema, oedema, burn depth, inflammatory cell infiltration, necrosis, ulceration, angiogenesis, neovascularization, fibroblast proliferation, collagenization, epithelization, fibrosis, the number of hair follicles and damage to the skin attachments. in the immunohistochemical examination of biopsy samples, samples will be taken for the evaluation of superoxide dismutase, malondialdehyde, myeloperoxidase in the evaluation of the tumour necrosis factor-alpha, interleukin-1β and oxidative stress in the ebb period in order to evaluate the acute phase reactants. fungal and gram staining will be done in order to determine the pathogen reproduction in biopsy samples taken on the 3rd and 7th day. masson trichrome in order to detect fibrosis in biopsy samples taken on the 14th and 21st day; hydroxyproline examination will be examined in order to evaluate collagen formation.


Eligibility criteria:
inclusion criteria: * adult (8-12 weeks) * 200-300 grams * wistar-albino rat * with 4 second-degree superficial contact burn are at its back. exclusion criteria: * the death of the rat in the research process

Keywords: burn burn wound propolis wound healing
the real-world data of risk factor and its prognosis in premature coronary artery disease study

Conditions: Premature Coronary Heart Disease

Summary: the goal of this observational study is to explore the relationship between biological aging and long-term prognosis of patients with metabolic cardiovascular disease in premature coronary artery disease. the main question\[s\] it aims to answer \[is/are\]: 1. do patients with premature coronary heart disease have accelerated biological aging? 2. what is the prognosis of accelerated biological aging in patients with premature coronary heart disease?


Eligibility criteria:
inclusion criteria: * male or female inpatients over 18 years old in the department of cardiovascular medicine; * patients with one of the following metabolic cardiovascular diseases \[17\]: including diabetes, hypertension, coronary heart disease, heart failure, cerebral infarction, dyslipidemia, obesity and hyperuricemia; * those who have corresponding inspection data so as to be able to calculate the biological age; * obtaining oral informed consent or signing an informed consent form; exclusion criteria: ·na

Keywords: premature coronary heart disease risk factor aging
intermittent hypoxia therapy in cardiac rehabilitation

Conditions: Cardiovascular Disease; Exercise; Hypoxia

Summary: this is a randomized control pilot study to assess the effect of intermittent hypoxia therapy on functional capacity vs conventional care in old patients with functional impairment admitted to a phase 2 in-hospital cardiac rehabilitation program.

because the improvement of exercise tolerance reduces mortality in elderly patients affected by cardiovascular disease, intermittent hypoxia therapy (iht) - defined as repeated episodes of hypoxia interspersed with normoxic periods delivered by an ad hoc device - might be a valuable tool to be associated to structured cardiac rehabilitation (cr) interventions. the present study is a pilot, monocentric, randomized (randomization ratio 1:1), parallel group study to assess the effect of iht on functional capacity vs conventional care in old patients with functional impairment admitted to a phase 2 in-hospital cardiac rehabilitation program. the study will enroll cardiac patients of both genders, ≥ 75 years and with a functional impairment assessed by a short physical performance battery (sppb) score \< 7. the effect of iht on functional capacity will be evaluated on top of the conventional multidisciplinary cr intervention, by means of sppb score variation; variations in quality of life and cognitive status will also be evaluated as secondary goals of the study. the total amount of iht sessions per patient will be 10, 1 per day over 2 weeks, the duration of each single procedure will be 45 min and the hypoxic o2 conc.% will be 14-10. the study was approved by local ethic committee.

Eligibility criteria:
inclusion criteria: * admission to a phase 2 in-hospital cardiac rehabilitation program because of a recent index event; * provision of signed and dated informed consent form; * age ≥ 75 years; * basic venous blood oxygen saturation (spo2) level \> 93% measured at the fingertip; * sppb score \< 7; * new york heart association (nyha) class i-iii. exclusion criteria: * inability to give informed consent (diminished understanding or comprehension); * age \< 75 years; * sppb score ≥ 7; * nyha class iv and/or concomitant i.v. therapy with cardiovascular active drugs; * uncontrolled angina pectoris; * uncontrolled arterial hypertension; * uncontrolled atrial or ventricular arrhythmias; * active pericarditis or myocarditis; * need of continuous or intermittent o2 therapy; * hb \< 10 g/dl; * severe concomitant non-cardiac diseases such as cancer or any other systemic disease limiting to participate in the study * acute inflammatory diseases; * acute non-cardiac somatic diseases, or somatic diseases with symptoms of decompensation; * currently implanted left ventricular assist device; * inability to accept the procedure of breathing via facial mask.

Keywords: cardiovascular disease rehabilitation exercise
simultaneous working length detection methods

Conditions: Irreversible Pulpitis; Root Canal Treatment

Summary: precise knowledge of the apical construction, which determines the end of the area for canal preparation and filling, is essential for the success of root canal treatment and the management of postoperative pain. for this purpose, devices based on various methods that determine the working length are used. however, it is still controversial which method provides the most accurate measurements.in this study, the compatibility of the electronic apex locator (eal) and simultaneous working length determination (swl) methods in single-root teeth was investigated in comparison with the radiographic working length determination method (rwl) method, and to determine which one produced more effective results in terms of postoperative pain.a hundred patients applied for endodontic treatment with a diagnosis of irreversible pulpitis (ip) were included in the study, which was planned as a single-center prospective cohort. patients were divided into three groups according to the method used to determine the root canal working length (wl). 35 patients in whom the wl with eal method (ewl) was used were included in group 1; 35 patients in whom the swl method was used were included in group 2; 30 patients in whom the rwl method was used were assigned to group 3. patient groups were randomly selected from people similar in age and gender. age, gender, simplified oral hygiene index (ohi-s), oral and dental examinations and visual analogue scale (vas) results of all participants were recorded.

devices that apply various methods to determine the root canal working length have been developed. the simultaneous working length determination is a newer development that allows clinicians to clean and shape root canals while monitoring the file's position inside the canal using dynamic feedback from eal. in this method, an endodontic motor with a built-in eal that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the wl. thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. the motor of devices using this method has automatic apical reverse and automatic apical stop operation. in this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating. thereby, swl method reduces the risk of over- instrumentation. in this study, planned in the light of the above information, the aim of this study was to investigate the compatibility of the ewl and swl methods in single-root teeth, in comparison with the rwl method, and to determine which one produces more effective results in terms of postoperative pain.

Eligibility criteria:
inclusion criteria: clinical diagnosis of irreversible pulpitis clinical indication for root canal treatment able to come for follow-ups exclusion criteria: cardiovascular disease antibiotic or antienflammatuary drug usage during last 3 months excess coronal structure damage for rubber dam placement

Keywords: working length irreversible pulpitis apex locator radiography simultaneous measurement
cycling study with the axonics system

Conditions: Overactive Bladder Syndrome; Urinary Urge Incontinence; Sacral Neuromodulation

Summary: a prospective, multi-center, study comparing continuous sacral neuromodulation (snm) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the axonics system.

after consent is provided, the required visits are at baseline, day 0, 1-month, and 3-month. at the follow-up visits, a bladder diary is reviewed, symptoms are assessed, the pgi-i questionnaire is completed, and cyclic stimulation hours may be changed.

Eligibility criteria:
inclusion criteria: 1. participants who are ≥ 21 years at the time of consent 2. has a primary indication of uui (participants with a secondary indication of uf or fi may also be enrolled) 3. has a diagnosis of uui for greater than or equal to 6 months prior to the date of consent 4. uui episodes: 1. for currently implanted participants (group a), they must be considered therapy responders with a \>50% reduction in uui episodes (based on their original baseline diaries) and satisfied with their snm therapy 2. for de novo candidates (group b), they must have completed a successful pne documented with a \>50% reduction in uui episodes on a 3-day diary (a diary must exist within a medical record or equivalent) 5. willing and capable of providing informed consent 6. agrees to return to the site for all study visits 7. fluent (able to speak and read) in english exclusion criteria: 1. any participant that the study investigator deems to be a poor candidate who is unable to complete a 72-hour bladder diary or will be non-compliant for study visits 2. diagnosis of urinary retention 3. surgical treatment for stress incontinence (e.g. sling, burch), and/or pelvic organ prolapse in the past 3 months or recommended or planned within 3 months from the time of consent 4. changes to current regimen of medications that could impact bladder function within 4 weeks prior to consent 5. current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture) 6. current symptomatic urinary tract infection (uti) 7. a patient who early discontinued from the artistry registry 8. a female with a positive urine pregnancy test 9. a female who is breastfeeding
effect of daily steps on fat metabolism

Conditions: Atherosclerosis; Metabolic Syndrome

Summary: reduced ambulatory activity has been shown to effect the response to a high fat tolerance test (hftt) after acute exercise. this study will evaluate the effect of varying levels of daily ambulation on response to a hftt after an acute aerobic exercise bout.


Eligibility criteria:
exclusion criteria: * cardiovascular problems (e.g. pre-existing heart issues, coronary artery disease, hypertension, etc.) * respiratory problems * musculoskeletal problems that prevent prolonged sitting or exercise * obesity * susceptibility to fainting * pregnancy